Annexon (ANNX) Common Equity (2019 - 2026)
Annexon (ANNX) posted quarterly Common Equity of $204.5 million for Q1 2026, down 16.1% year-over-year from $243.8 million in Q1 2025, and down 3.36% quarter-over-quarter from $211.6 million in Q4 2025.
Annexon (ANNX) Common Equity (2019 - 2026) Analysis & Trends
Annexon's Common Equity history runs 8 years deep, the most recent figure standing at $204.5 million for Q1 2026.
- In Q1 2026, Common Equity fell 16.1% year-over-year to $204.5 million; the TTM figure through Mar 2026 stood at $204.5 million (down 16.1% YoY), while the FY2025 annual figure was $211.6 million, down 27.79% from the prior year.
- Common Equity for Q1 2026 stood at $204.5 million, down from $211.6 million in the prior quarter.
- The five-year high for Common Equity was $361.1 million in Q2 2024, with the low at $156.8 million in Q3 2023.
- The 5-year median for Common Equity is $214.9 million (2023), against an average of $231.5 million.
- The sharpest annual moves came in 2024 and 2025: Common Equity surged 111.4% in 2024, then tumbled 51.31% in 2025.
- Annexon's Common Equity stood at $231.2 million in 2022, then gained by 8.37% to $250.6 million in 2023, then rose by 16.98% to $293.1 million in 2024, then fell by 27.79% to $211.6 million in 2025, then slipped by 3.36% to $204.5 million in 2026.
- Business Quant data shows ANNX's Common Equity at $204.5 million in Q1 2026, $211.6 million in Q4 2025, and $161.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Annexon | 1.00 Bn | 1.00 Bn | - | 186.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 186.06 Mn |
| Mar 31, 2026 | 204.53 Mn |
| Dec 31, 2025 | 211.65 Mn |
| Sep 30, 2025 | 161.44 Mn |
| Jun 30, 2025 | 199.02 Mn |
| Mar 31, 2025 | 243.79 Mn |
| Dec 31, 2024 | 293.11 Mn |
| Sep 30, 2024 | 331.56 Mn |
| Jun 30, 2024 | 361.08 Mn |
| Mar 31, 2024 | 262.41 Mn |
| Dec 31, 2023 | 250.56 Mn |
| Sep 30, 2023 | 156.84 Mn |
| Jun 30, 2023 | 184.72 Mn |
| Mar 31, 2023 | 214.86 Mn |
| Dec 31, 2022 | 231.19 Mn |
| Sep 30, 2022 | 260.60 Mn |
| Jun 30, 2022 | 168.04 Mn |
| Mar 31, 2022 | 200.61 Mn |
| Dec 31, 2021 | 231.91 Mn |
| Sep 30, 2021 | 264.48 Mn |